Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

152.60 -2.67 (-1.72%)
Streaming Delayed Price Updated: 3:30 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
News headline image
Market Monitor News August 22 BMO - Coty Crumbles, Powell Looms: Wall Street Cautious Amid Mixed Signals ↗
Markets dipped Thursday as Coty issued a dismal forecast, Gilead faced headwinds with its new HIV drug, and investors turned cautious ahead of Fed Chair Powell’s Jackson Hole speech. Solid PMI data... 
Via Chartmill
Topics Economy
News headline image
Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy ↗
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access. 
Via Benzinga
News headline image
Why Gilead Sciences (GILD) Shares Are Sliding Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to... 
Via StockStory
Topics Earnings
News headline image
These S&P500 stocks are gapping in today's session ↗
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
CVS Health Reportedly Keeps Gilead’s New HIV Preventative Shot Off Its Plans, Faces $290M Medicare Fraud Ruling ↗
Via Stocktwits
Topics Fraud
Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant ↗
Via Stocktwits
News headline image
Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug ↗
Insurance coverage is key for any new drug. But it's looking tenuous for Gilead Sciences' newest HIV prevention drug. 
Via Investor's Business Daily
News headline image
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans ↗
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties. 
Via Benzinga
News headline image
Walgreens Grows Specialty Pharmacy Network To Meet Rising Demand For Complex Therapies ↗
Walgreens boosts specialty drug network to 265 therapies, reinforcing its independent market position. 
Via Benzinga
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) Presents a Compelling Case for Value Investors ↗
Gilead Sciences (GILD) appears undervalued with strong profitability, a solid dividend, and moderate growth, offering a compelling case for value investors. 
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Xilio Revenue Jumps 246 Percent in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions
Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and the launch of Yeztugo, its twice-yearly injectable for HIV prevention.... 
Via StockStory
Topics Earnings
News headline image
Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Is Gilead Sciences Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s... 
Via StockStory
News headline image
Kymera Revenue Drops 55 Percent in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Market Monitor News August 11 BMO - Nasdaq Breaks Records, But The Trade Desk Hits a Wall ↗
Markets ended the week in high spirits, but not everyone joined the party. 
Via Chartmill
News headline image
Gilead Sciences Shares Soar; Analysts Lift Targets On HIV Strength And Yeztugo Outlook ↗
Upbeat guidance boosts confidence despite competitive pressures. 
Via Talk Markets
News headline image
Wall Street's Resilient Rally: What's Driving the Positive Momentum
Wall Street has experienced a broadly positive day, marked by a resilient rally that has added over $1 trillion in market value. This surge in investor confidence is primarily driven by a confluence of... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
Earnings Season Boosts Confidence: Gilead and Expedia Lead Strong Corporate Results
The second quarter 2025 earnings season has largely concluded, delivering a powerful shot of optimism to the financial markets. Against a backdrop of persistent economic uncertainties and geopolitical... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Top S&P500 movers in Friday's session ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
News headline image
Tech Stocks Eye Record Highs As Magnificent Seven Top $19.5 Trillion: What's Moving Markets Friday? ↗
Tech stocks staged a full rebound from last Friday's sell-off, with the Nasdaq 100 surging to 23,600 — just shy of the 23,700 all-time high set in late July, as the week’s strong sector earnings and... 
Via Benzinga
News headline image
Earnings Season Highlights: Gilead Sciences and Expedia Group Post Strong Results
The second quarter of 2025 has largely concluded as a period of unexpected strength for U.S. corporations, with a significant number of companies not only meeting but exceeding analyst expectations.... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Friday's session: top gainers and losers in the S&P500 index ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday. 
Via Chartmill
News headline image
Why Is Gilead Sciences (GILD) Stock Rocketing Higher Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.7% in the morning session after the company reported second-quarter 2025 results that topped Wall Street's expectations and... 
Via StockStory
Topics Earnings
News headline image
Gilead Lifts Annual Outlook As Yeztugo Launch Nears ↗
Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales. 
Via Benzinga
News headline image
SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Discover the top S&P500 movers in Friday's pre-market session. ↗
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
News headline image
Gilead Sciences (GILD) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.